

PTO/SB/08B (10-01)

Approved for use through 10/31/2002, OMB 0651-0031

U. S. Patent and Trademark Office: U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.


Substitute for form 1449B/PTO		Complete If Known	
		Application Number	10/023,530
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Filing Date	December 18, 2001
		First Named Inventor	Pierre Legrain
		Group Art Unit	4645 / 636
		Examiner Name	Not Yet Assigned
		Attorney Docket Number	EGYPSA 3.0-001
Sheet	2	of	3

RECEIVED

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
DS	CA	ROBERT SERVICE "Protein arrays step out of DNA's shadow," 289 Science (2000) 16.	
	CB	MACBEATH & SCHREIBER, "Printing proteins as microarrays for high-throughput function determination," 289 Science (2000) 1760-63.	
	CC	ZIJLSTRA et al., "Germ-line transmission of a disrupted β 2-microglobulin gene produced by homologous recombination in embryonic stem cells," 342 Letters to Nature (1989) 435-38.	
	CD	WU & WU "Receptor-mediated in vitro gene transformation by a soluble DNA carrier system," 262 J. Biol. Chem. (1987) 4429-32.	
	CE	JACOBY et al., "Hybrid vectors: a new generation of virus-based vectors designed to control the cellular fate of delivered genes," 4 Gene Therapy (1997) 1281-83.	
	CF	STEPHEN KOCHANNEK, "High-capacity adenoviral vectors for gene transfer and somatic gene therapy," 10 Human Gene Therapy (1999) 2451-59.	
	CG	MILLER et al., "Use of Retroviral Vectors for Gene Transfer and Expression," 217 Methods in Enzymology Recombinant DNA Part H (1993) 581-99.	
	CH	ROBBINS & GHIVIZZANI "Viral Vectors for Gene Therapy," 80 Pharmacology & Therapeutics (1998) 35-47.	
	CI	VASAVADA et al. "A contingent replication assay for the detection of protein-protein interactions in animal cells," 88 Proc. Natl. Acad. Sci. (1991) 10686-90.	
	CJ	TAKACS et al. "Mapping of interacting domains between the nucleocapsid protein and the phosphoprotein of vesicular stomatitis virus by using a two-hybrid system," 90 Proc. Natl. Acad. Sci. (1993) 10375-79.	
	CK	SZABO et al. "Surface plasmon resonance and its use in biomolecular interaction analysis (BIA) 5 Current Opinion in Structural Biology (1995) 699-705.	
	CL	PEARSON & LIPMAN "Improved tools for biological sequence comparison," 85 Proc. Natl. Acad. Sci. (1988) 2444-8.	
	CM	NEEDLEMAN & WUNSCH, "A general method applicable to the search for similarities in the amino acid sequence of two proteins," 48 J. Molecular Biology (1970) 443-53.	
	CN	SMITH & WATERMAN "Overlapping genes and information theory" Letter to the Editor, 91 J. Theoretical Biology (1981) 379-80.	
	CO	BRENT & FINLEY "Understanding gene and allele function with two-hybrid methods," 31 Annual Review of Genetics (1997) 663-704.	
	CP	LEGRAIN & SELIG "Genome-wide protein interaction maps using two-hybrid systems," 480 FEBS Letters (2000) 32-36.	
	CQ	VIDAL & LEGRAIN "Yeast forward and reverse 'n'-hybrid systems," 27 Nucleic Acids Research (1999) 919-29.	
	CR	EDWARDS & LEATHERBARROW "Determination of Association rate constants by an optical biosensor using initial rate analysis," 246 Analytical Biochemistry (1997) 1-6.	
	CS	MARGOTTIN et al, "A novel human WD protein, h- β TrCP that interacts with HIV-1 Vpu connects CD4 to the ER degradation pathway through an F-box motif," 1 Molecular Cell (1988) 565-74.	
	CT	FIELDS & SONG "A novel genetic system to detect protein-protein interactions," 340 Nature (1989) 245-6.	
	CU	DAMMANN et al "Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3" 25 Nature Genetics (2000) 315-19.	
	CV	VIDAL et al. "Reverse two-hybrid and one-hybrid systems to detect dissociation of protein-protein and DNA-protein interactions" 93 Proc. Natl. Acad. Sci USA (1996) 10315-20.	
DS	CW	TIRODE et al. "A conditionally expressed third partner stabilizes or prevents the formation of a transcriptional activator in a three-hybrid system," 272 J. Biol. Chemistry (1997) 22995-99.	

D. S. Full

10/1/03



PTO/SB/08B (10-01)


Approved for use through 10/31/2002. OMB 0651-0031

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Project of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.


Substitute for form 1449b/PTO		Complete if Known	
		Application Number	10/023,530
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Filing Date	December 18, 2001
		First Named Inventor	Pierre Legrain
		Group Art Unit	4645 1636
		Examiner Name	Not Yet Assigned
		Attorney Docket Number	EGYPSA 3.0-001
Sheet	3	of	3

DS	CX	REYNOLDS et al., "Chimeric viral vectors -- the best of both worlds?" Molecular Medicine Today (1999) 25-31.	
	CY	GOLDSPIEL et al. "Clinical Frontiers; Human gene therapy," 12 Clin. Pharm. (1993) 488-505.	
	CZ	PATTON et al. "Combinatorial control in ubiquitin-dependent proteolysis: don't Skp the F-box hypothesis," 14 Trends Genet. (1998) 236-43.	
	CA1	KOEPP et al. "How the Cyclin Became a Cyclin: Regulated Proteolysis in the Cell Cycle," 97 Cell (1999) 431-34.	
	CB1	R.J. DESHAIES "SCF and Cullin/RING H2-Based Ubiquitin Ligases," 15 Annual Review of Cell Dev. Biol. (1999) 425-67.	
	CC1	SKOWRYA et al. "F-box proteins are receptors that recruit phosphorylated substrates to the SCF ubiquitin-ligase complex," 91 Cell (1997) 209-19.	
	CD1	FELDMAN et al. "A complex of Cdc4p, Skp1p, and Cdc53p/Cullin catalyzes ubiquitination of the phosphorylated CDK inhibitor Sic1p," 91 Cell (1997) 221-30.	
	CE1	VOS et al. "Ras uses the novel tumor suppressor RASSF1 as an effector to mediate apoptosis," 274 J. Biol. Chem. (2000) 35669-72.	
	CF1	SELIG et al. "Interaction with the p6 domain of the gag precursor mediates incorporation into virions of Vpr and Vpx proteins from primate lentiviruses," 73 J. Virol. (1999) 592-600.	
	CG1	LASSOT et al., "ATF4 degradation relies on a phosphorylation-dependent interaction with the SCF- β TrCP ubiquitin ligase," 21 Mol. Cell. Biol. (2001) 2192-2202.	
	CH1	MORRISEY et al., "Epigenetic inactivation of the RASSF1A 3p21.3 tumor suppressor gene in both clear cell and papillary renal cell carcinoma" 61 Cancer Res. (2001) 7277-81. .	
	CI1	AGATHANGGELOU et al., "Methylation associated inactivation of RASSF1A from region 3p21.3 in lung, breast and ovarian tumours," 20 Oncogene. (2001) 1509-18.	
	CJ1	ELBASHIR et al. "Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells," 411 Nature (2001) 494-8.	
DS	CK1	HART et al., "The F-box protein β TrCP associates with phosphorylated beta-catenin and regulates its activity in cells," 9 Curr. Biol. (1999) 207-10.	

Examiner Signature		Date Considered	10/1/03
--------------------	---	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.



#7

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U. S. Patent and Trademark Office: U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/023,530
				Filing Date	December 18, 2001
				First Named Inventor	Pierre Legrain
				Art Unit	4045-1636
				Examiner Name	Not Yet Assigned
Sheet	1	of	3	Attorney Docket Number	EGYPSA 3.0-001

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
DS	AA	5468614	11-21-1995	Fields et al.	435/6
	AB	4980286	12-25-1990	Morgan et al.	435/172.3
	AC	5667973	09-16-1997	Fields et al.	435/6
	AD	5283173	02-01-1994	Fields et al.	435/6

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
DS	BA	WO 00/66722	11-09-2000	Hybrigenics		
	BB	WO 99/42612	08-26-1999	Institut Pasteur		
	BC	WO 00/07038	02-10-2000	Universite de Montreal		
	BD	WO 98/34120	08-06-1998	Universite de Montreal		
	BE	WO 99/28746	06-10-1999	Institut Pasteur		
	BF	WO 92/06180	04-16-1992	University of Connecticut		
	BG	WO 93/14188	07-22-1993	The Regents of the University of Michigan		
	BH	WO 93/20221	10-14-1993	Alexander Young		

Examiner Signature	<i>DS</i>	Date Considered	10/1/03
-----------------------	-----------	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

¹ Applicant's unique citation designation number (optional). ² See attached Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the application number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

RECEIVED

JUL 08 2002